[1] 孙哲, 杨文娟, 王瑞麟, 等. 基于回顾性队列的阿托伐他汀钙仿制药与原研药安全性和经济性评价及危险因素评估[J]. 中国医院药学杂志, 2022, 42(14): 1447
SUN Z, YANG WJ, WANG RL,
et al. Retrospective comparative study on safety economy and risk assessment of the generic and branded atorvastatin calcium[J]. Chin J Hosp Pharm, 2022, 42(14): 1447
[2] 惠春, 林大专, 孙莹. 阿托伐他汀致不良反应24例文献分析[J]. 中国药房, 2010, 21(44): 4189
HUI C, LIN DZ, SUN Y. Literature analysis of 24 adverse drug reactions cases caused by atorvastatin[J]. China Pharm, 2010, 21(44): 4189
[3] GHIM JL, PHUONG NTT, KIM MJ,
et al. Pharmacokinetics of fixed-dose combination of atorvastatin and metformin compared with individual tablets[J]. Drug Des Devel Ther, 2019, 13: 1623
[4] TURNER RM, FONTANA V, BAYLISS M,
et al. Development, validation and application of a novel HPLC-MS/MS method for the quantification of atorvastatin, bisoprolol and clopidogrel in a large cardiovascular patient cohort[J]. J Pharm Biomed Anal, 2018, 159: 272
[5] HERMANN M, BOGSRUD MP, MOLDEN E,
et al. Exposure of atorvastatin is unchanged but lactone and acid metabolites are increased several-fold in patients with atorvastatin-induced myopathy[J]. Clin Pharmacol Ther, 2006, 79(6): 532
[6] 易志恒, 李筱旻, 申秋莹, 等. LC-MS-MS法测定人血浆中阿托伐他汀、邻位阿托伐他汀和对位阿托伐他汀的浓度[J]. 中南药学, 2021, 19(12): 2564
YI ZH, LI YW, SHEN QY,
et al. LC-MS-MS determination of atorvastatin,ortho-hydroxy atorvastatin and para-hydroxy atorvastatin in human plasma[J]. Cent South Pharm, 2021, 19(12): 2564
[7] CHOI YK, PARK SE, KIM EY,
et al. Pharmacokinetics of atorvastatin and sustained-release metformin fixed-dose combination tablets: two randomized, open-label, 2-way crossover studies in healthy male subjects under fed conditions[J]. Transl Clin Pharmacol, 2017, 25(4): 190
[8] 梁美芳, 陈庆状, 杨沛群, 等. 基于真实世界的阿托伐他汀仿制药和原研药防治缺血性脑卒中/短暂性脑缺血发作的有效性和安全性比较[J]. 中国临床药理学与治疗学, 2022, 27(7): 785
LIANG MF, CHEN QZ, YANG PQ,
et al. Efficacy and safety of generic and branded atorvastatin in patients with ischemic stroke/transient ischemic attack: a real-world study[J]. Chin J Clin Pharmacol, 2022, 27(7): 785
[9] KNEBEL W, GASTONGUAY MR, MALHOTRA B,
et al. Population pharmacokinetics of atorvastatin and its active metabolites in children and adolescents with heterozygous familial hypercholesterolemia: selective use of informative prior distributions from adults[J]. J Clin Pharmacol, 2013, 53(5): 505
[10] 吕斌, 寻添荣, 吴树龙, 等. HPLC-MS/MS同时检测大鼠血浆中阿托伐他汀和伏立康唑的浓度[J]. 南方医科大学学报, 2019, 39(3): 337
LÜ B, XUN TR, WU SL,
et al. Interaction between atorvastatin and voriconazole in rat plasma: a HPLC-MS/MS based study[J]. J South Med Univ, 2019, 39(3): 337
[11] 易小翠. 基于液相色谱-质谱联用法的苯二氮
![]()
类药物分析方法的建立及在大鼠体内药代动力学的研究[D]. 宜春: 宜春学院, 2021
YI XC. Establishment of Analytical Method for Benzodiazepine and Study of Pharmacokinetics in Rats by LC-MS[D]. Yichun: Yichun University, 2021
[12] HWANG JG, YU KS, LEE S. Comparison of the pharmacokinetics of highly variable drugs in healthy subjects using a partial replicated crossover study: a fixed-dose combination of fimasartan 120 mg and atorvastatin 40 mg versus separate tablets[J]. Drug Des Devel Ther, 2020, 14: 1953
[13] ANDERSON K, NELSON CH, GONG Q,
et al. Assessment of the effect of filgotinib on the pharmacokinetics of atorvastatin, pravastatin, and rosuvastatin in healthy adult participants[J]. Clin Pharmacol Drug Dev, 2022, 11(2): 235
[14] FDA. Bioanalytical-Method-Validation-Guidance-Industry[S]. 2018
[15] HUANG F, MARZIN K, KOENEN R,
et al. Effect of steady-state faldaprevir on pharmacokinetics of atorvastatin or rosuvastatin in healthy volunteers: a prospective open-label, fixed-sequence crossover study[J]. J Clin Pharmacol, 2017, 57(10): 1305
[16] 罗楠, 谭力, 张玫, 等. LC-MS/MS测定大鼠血浆中阿托伐他汀及其活性代谢产物[J]. 中国现代应用药学, 2019, 36(9): 1029
LUO N, TAN L, ZHANG M,
et al. Determination of atorvastatin and its active metabolites in plasma of rat by LC-MS/MS[J]. Chin J Mod Appl Pharm, 2019, 36(9): 1029
[17] 孙斌, 魏振满, 郭晓东, 等. LC-MS/MS定量测定人体血浆中阿托伐他汀浓度[J]. 现代生物医学进展, 2013, 13(13): 2565
SUN B, WEI ZM, GUO XD,
et al. Quantitative determination of the atorvastatin concentration in healthy human plasma by LC-MS/MS[J]. Prog Mod Biomed, 2013, 13(13): 2565
[18] 姜楠, 杨永革, 许雪廷, 等. LC-MS-MS法测定人血浆中阿托伐他汀浓度[J]. 药学实践杂志, 2011, 29(1): 15
JIANG N, YANG YG, XU XY,
et al. Determination of atorvastatin in human plasma by LC-MS-MS[J]. J Pharm Pract, 2011, 29(1): 15
[19] 陈菡菁, 徐红蓉, 苑菲, 等. LC-MS/MS法同时测定人血浆中阿托伐他汀及其活性代谢物的浓度[J]. 中国临床药理学杂志, 2017, 33(6): 542
CHEN HQ, XU HR, YUAN F,
et al. Simultaneous determination of atorvastatin and its active metabolites in human plasma by LC-MS/MS[J]. Chin J Clin Pharmacol, 2017, 33(6): 542
[20] 丁杨明, 王晓雪, 陈瑶, 等. UPLC-MS/MS法同时测定人血浆样本中瑞舒伐他汀、阿托伐他汀及其代谢物的浓度[J]. 国际药学研究杂志, 2020, 47(3): 236
DING YM, WANG XX, CHEN Y,
et al. Simultaneous determination of rosuvastatin,atorvastatin and their metabolites in human plasma by UPLC-MS/MS[J]. J Int Pharm Res, 2020, 47(3): 236
[21] BAGGETT MC, NYKAMP D. Statin-associated bilateral foot myopathy[J]. J Pharm Pract, 2020, 33(6): 899
[22] LINS RL, MATTHYS KE, VERPOOTEN GA,
et al. Pharmacokinetics of atorvastatin and its metabolites after single and multiple dosing in hypercholesterolaemic haemodialysis patients[J]. Nephrol Dial Transplant, 2003, 18(5): 967
[23] HERMANN M, BOGSRUD MP, MOLDEN E,
et al. Exposure of atorvastatin is unchanged but lactone and acid metabolites are increased several-fold in patients with atorvastatin-induced myopathy[J]. Clin Pharmacol Ther, 2006, 79(6): 532
[24] GIBSON DM, BRON NJ, RICHENS A,
et al. Effect of age and gender on pharmacokinetics of atorvastatin in humans[J]. J Clin Pharmacol, 1996, 36(3): 242
[25] SKOTTHEIM IB, BOGSRUD MP, HERMANN M,
et al. Atorvastatin metabolite measurements as a diagnostic tool for statin-induced myopathy[J]. Mol Diagn Ther, 2011, 15(4): 221
[26] AMSDEN GW, KUYE O, WEI GC. A study of the interaction potential of azithromycin and clarithromycin with atorvastatin in healthy volunteers[J]. J Clin Pharmacol, 2002, 42(4): 444
[27] PATEL AM, SHARIFF S, BAILEY DG,
et al. Statin toxicity from macrolide antibiotic coprescription: a population-based cohort study[J]. Ann Intern Med, 2013, 158(12): 869
[28] LENNERNÄS H. Clinical pharmacokinetics of atorvastatin[J]. Clin Pharmacokinet, 2003, 42(13): 1141
